Based on the Prothena Corporation plc stock forecast from 4 analysts, the average analyst target price for Prothena Corporation plc is USD 30.50 over the next 12 months. Prothena Corporation plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Prothena Corporation plc is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Prothena Corporation plc’s stock price was USD 9.30. Prothena Corporation plc’s stock price has changed by -6.44% over the past week, -28.30% over the past month and -56.05% over the last year.
No recent analyst target price found for Prothena Corporation plc
No recent average analyst rating found for Prothena Corporation plc
Company Overview Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland. Read Less
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, ...Read More
Frequently Asked Questions About Prothena Corporation plc (PRTA) Stock
Based on ratings from 4 analysts Prothena Corporation plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 4 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on PRTA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for PRTA is USD 30.50 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 20.
PRTA stock's Price/Earning ratio is 34.95.
Our analysis grades PRTA stock's Price / Earning ratio at F. This means that PRTA stock's Price/Earning ratio is above 79% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PRTA may be a overvalued for its sector.
The last closing price of PRTA's stock was USD 9.30.
The most recent market capitalization for PRTA is USD 0.71B.
Based on targets from 4 analysts, the average taret price for PRTA is projected at USD 30.50 over the next 12 months.
This means that PRTA's stock price may go up by +227.96% over the next 12 months.
We can't find any ETFs which contains Prothena Corporation plc's stock.
As per our most recent records Prothena Corporation plc has 163 Employees.
Prothena Corporation plc's registered address is 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60.
You can get more information about it from Prothena Corporation plc's website at https://www.prothena.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Prothena Corporation plc (PRTA) Stock
Based on ratings from 4 analysts Prothena Corporation plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 4 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on PRTA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for PRTA is USD 30.50 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 20.
PRTA stock's Price/Earning ratio is 34.95.
Our analysis grades PRTA stock's Price / Earning ratio at F. This means that PRTA stock's Price/Earning ratio is above 79% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PRTA may be a overvalued for its sector.
The last closing price of PRTA's stock was USD 9.30.
The most recent market capitalization for PRTA is USD 0.71B.
Based on targets from 4 analysts, the average taret price for PRTA is projected at USD 30.50 over the next 12 months.
This means that PRTA's stock price may go up by +227.96% over the next 12 months.
We can't find any ETFs which contains Prothena Corporation plc's stock.
As per our most recent records Prothena Corporation plc has 163 Employees.
Prothena Corporation plc's registered address is 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60.
You can get more information about it from Prothena Corporation plc's website at https://www.prothena.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PRTA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
